Future Therapies Modeled After Johnson & Johnson/Basilea's or Forest/Novexel's Drug Could Be Used As First-Line Therapies, According to a New Report from AMR and Decision Resources
MALVERN, Pa. and WALTHAM, Mass., Feb. 24 /PRNewswire/ -- Arlington Medical Resources (AMR) and Decision Resources find that activity against drug-resistant pathogens is one of the leading drug attributes influencing surveyed physicians' antibiotic selection for the treatment of inpatient community-acquired pneumonia. Due to the difficulty of obtaining adequate samples for microbiological testing, physicians rely on empiric therapies that can cover key pathogens, particularly resistant and susceptible strains of Streptococcus pneumoniae. In fact, one of the key trends surveyed physicians foresee in the next five years is to prescribe an empiric therapy that covers methicillin-resistant Staphylococcus aureus (MRSA) for inpatients with community-acquired pneumonia.
The new report entitled Hospital Anti-Infectives Insight Series: Community-Acquired Pneumonia also finds that future therapies modeled after Johnson & Johnson/Basilea's ceftobiprole or Forest/Novexel's ceftaroline could be used as empiric first-line therapies for very severe cases of community-acquired pneumonia requiring admission to the ICU or mechanical ventilation.
"Ceftobiprole and ceftaroline couple broad-spectrum cephalosporin activity with targeted activity against MRSA, offering physicians enhanced pathogen coverage for empiric treatment of community-acquired pneumonia in the hospital setting," stated Lisa Arias, analyst at Decision Resources. "We anticipate that future therapies modeled after these agents will gain substantial usage in the market for the treatment of inpatient community-acquired pneumonia and potentially displace usage of older, generically available cephalosporins, due to their anti-MRSA activity."
About Hospital Anti-Infectives Insight Series
AMR and Decision Resources' new Hospital Anti-Infectives Insight Series analyzes hospital antibiotic prescribing patterns using AMR's comprehensive and highly detailed clinical data in conjunction with Decision Resources' disease area knowledge, primary research and extensive understanding of emerging therapies and forecasts. These reports examine the reasons behind physicians' product preferences, factors driving hospital antibiotic prescribing patterns and receptivity to emerging antibiotics.
AMR (www.AMR-data.com) serves the market intelligence needs of the pharmaceutical and diagnostic imaging industries. Research includes clinical inpatient databases that directly link anti-infective drug with indication/procedure, formulary and stocking status tracking studies, drug purchasing audits and diagnostic imaging procedure volume/contrast media usage audits. AMR is a Decision Resources, Inc. company.
About Decision Resources
Decision Resources (www.DecisionResources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.
About Decision Resources, Inc.
Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.
All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.
For more information, contact: Natalia Morales Elizabeth Marshall Decision Resources Decision Resources, Inc. 781-296-2691 781-296-2563 email@example.com firstname.lastname@example.org
|SOURCE Decision Resources|
Copyright©2009 PR Newswire.
All rights reserved